NCT06941272 2026-03-13
MK-9999-01C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
150 trialsNCT02908906 2026-03-12
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT04333706 2026-03-10
EMPOWER
University of Southern California
Phase 1/2 Recruiting
NCT04723810 2026-03-09
TumorGlow Intraoperative Molecular Imaging (IMI)
University of Pennsylvania
Phase 1/2 Recruiting
NCT07354100 2026-03-04
(BLOOM)
University of Chicago
Phase 1/2 Not yet recruiting
NCT06014658 2026-03-02
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
MBrace Therapeutics
Phase 1/2 Recruiting
NCT06056791 2026-02-27
CaRe
Inmune Bio, Inc.
Phase 1/2 Completed
NCT07276373 2026-02-27
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
Phase 1/2 Recruiting
NCT06818643 2026-02-19
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06211933 2026-02-12
PULS
Centre Leon Berard
Phase 1/2 Suspended
NCT04078295 2026-02-10
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT06634849 2026-02-10
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Pathios Therapeutics Pty Ltd
Phase 1/2 Recruiting
NCT03260023 2026-02-05
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Transgene
Phase 1/2 Active not recruiting
NCT06077877 2026-02-02
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT04260529 2026-01-29
CICILIA
Cytovation AS
Phase 1/2 Completed
NCT03872778 2026-01-28
NeoRay
Advanced Accelerator Applications
Phase 1/2 Completed
NCT04145622 2026-01-28
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1/2 Recruiting
NCT06840119 2026-01-28
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Immunocore Ltd
Phase 1/2 Recruiting
NCT07112222 2026-01-26
A Study of LM-350 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT07073534 2026-01-22
Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05741242 2026-01-15
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Phase 1/2 Enrolling by invitation
NCT05450562 2026-01-14
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT07197827 2025-12-24
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT05383170 2025-11-28
Catalyst
Cytovation AS
Phase 1/2 Completed
NCT05516914 2025-11-28
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT06311851 2025-11-25
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Pardis Noor Medical Imaging and Cancer Center
Phase 1/2 Recruiting
NCT06184035 2025-11-20
Tumorad
Spago Nanomedical AB
Phase 1/2 Recruiting
NCT03363893 2025-11-12
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT02130492 2025-10-23
A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)
Weill Medical College of Cornell University
Phase 1/2 Suspended
NCT06796907 2025-10-14
BEHOLD-2
GlaxoSmithKline
Phase 1/2 Recruiting
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05697406 2025-09-22
HC-MRI
University of Maryland, Baltimore
Phase 1/2 Recruiting
NCT06193902 2025-09-03
AERIAL
Leucid Bio
Phase 1/2 Recruiting
NCT04717375 2025-08-07
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT05046171 2025-07-22
Decreasing Polypharmacy in Older Adults With Curable Cancers Trial
University of Rochester
Phase 1/2 Active not recruiting
NCT02637687 2025-06-22
SCOUT
Bayer
Phase 1/2 Active not recruiting
NCT07032142 2025-06-22
ARCTURUS
D'Or Institute for Research and Education
Phase 1/2 Not yet recruiting
NCT05413473 2025-06-15
Northern Alberta Linac-MR Image-Guided Radiotherapy (Northern LIGHTs-2)
AHS Cancer Control Alberta
Phase 1/2 Recruiting
NCT06987500 2025-06-06
A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
Evopoint Biosciences Inc.
Phase 1/2 Recruiting
NCT04706715 2025-05-31
LAG3 PET Imaging in Advanced Solid Tumors
University Medical Center Groningen
Phase 1/2 Active not recruiting
NCT05674825 2025-05-15
MCW I-PREDICT
Medical College of Wisconsin
Phase 1/2 Recruiting
NCT06650566 2025-05-02
Study of LM-299 in Subjects Advanced Malignant Tumors
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT05120596 2025-04-25
First in Human Study of T3P-Y058-739 (T3P)
T3 Pharmaceuticals AG
Phase 1/2 Recruiting
NCT06911333 2025-04-04
AD1208
Avelos Therapeutics Inc.
Phase 1/2 Recruiting
NCT05269316 2025-04-01
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Impact Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06827080 2025-02-14
Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer
Mianyang Central Hospital
Phase 1/2 Not yet recruiting
NCT05615974 2024-12-19
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT05918445 2024-12-05
PM8002 in the Treatment of Patients With Advanced Solid Tumors
Biotheus Inc.
Phase 1/2 Recruiting